Under the terms of the new agreement, NascaCell receives non-exclusive rights to uses of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design.
Future aptamer technology improvements will be cross-licensed between the companies and Archemix will have the option of contracting NascaCell to generate aptamers for its own applications.